Clinical and pharmacological group: Oral - hypoglycemic drug
Active substance
- dapagliflozin (dapagliflozin)
Indications:
Type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control as:
monotherapy;
combination therapy with metformin, sulfonylurea derivatives (incl. in combination with metformin), thiazolidinediones, dipeptidyl peptidase 4 inhibitors (DPP-4) (incl. in combination with metformin), glucagon-like polypeptide-1 receptor agonist (GLP-1) exenatide of prolonged action in combination with metformin, insulin preparations (in incl. in combination with one o
...r two hypoglycemic drugs for oral administration) in the absence of adequate glycemic control on this therapy;
starting combination therapy with metformin, if this therapy is appropriate.
Contraindications
increased individual sensitivity to any component of the drug;
type 1 diabetes mellitus;
diabetic ketoacidosis;
renal insufficiency with calculated GFR consistently less thaShow more